The physiological disposition of lovastatin

Area of Science:

• Pharmacology
• Biochemistry
• Drug Metabolism

Background:

• Lovastatin is a pro-drug lactone.
• Its active form, beta-hydroxy-acid (HA), inhibits cholesterol synthesis by targeting HMG-CoA reductase.
• The liver is the primary site for cholesterol synthesis and thus a key target organ for statins.

Purpose of the Study:

• To compare the absorption, distribution, metabolism, and excretion (ADME) profiles of lovastatin and its active metabolite in animal models.
• To identify the most appropriate animal model for human studies on lovastatin disposition.

Main Methods:

• Comparative analysis of lovastatin and HA ADME profiles across different animal species.
• Investigation of hepatic extraction and biotransformation pathways.
• Assessment of systemic drug burden and tissue distribution.

Main Results:

• Lovastatin is less absorbed than HA but is efficiently extracted by the liver.
• The liver reversibly converts lovastatin to HA and irreversibly to other active metabolites.
• High hepatic gradients of HA are maintained, with minimal systemic levels attributed to metabolic equilibrium.
• Biliary excretion is the predominant route of elimination in all species studied.
• Dogs demonstrated ADME profiles most similar to humans.

Conclusions:

• Dogs are the most suitable animal model for studying human lovastatin disposition.
• The liver's efficient metabolism and biliary excretion contribute to controlled systemic exposure to lovastatin's active forms.